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Introduction/Objectives: Botulinum toxin is one 
of the most potent biologic poisons known. Botuli-
num toxin proteins have been studied since 1900s, 
initially to understand botulism, a form of food poi-
soning. Later, they were studied because of the use of 
the toxins for treatment of muscle hyperactivity due to 
muscle paralysis induced by small amounts of the tox-
ins. Th e 7 distinct serotypes A, B, C, D, E, F, and G 
are of similar structures. However, the serotypes dif-
fer in their cellular target sites, potency and duration 
of action. Types A and B have been shown eff ective 
and safe in clinical trials for the treatment of move-
ment disorders and spasticity.
Participants, Materials/Methods: One of the 
most common movement disorders treated with bot-
ulinum toxin type-A (BTX-A) is focal dystonia (the 
most frequent cervical dystonia, followed by blephar-
ospasm, oromandibular dystonia, occupational-hand 
dystonia, and laryngeal dystonia. Compared to gen-
eral population, a negative impact of focal dystonia 
on health related quality of life (HRQL) was found. 
BTX-A treatment signifi cantly improves several 
HRQL dimensions. Dystonia infl uences various as-
pects of QoL, particularly those related to physicial 
and social functioning. A total of 76 cervical dystonia 
(CD) patients were studied during 3 years of BTX-A 
treatment. Beck Depression Score (BDS) and HRQoL 
assessment were investigated in all patients before and 
after BTX-A treatment.
Results: Results of our study indicate that func-
tional disability and depression were the best pre-
dictors of QoL in focal dystonia. BTX-A treatment 
signifi cantly reduced depression in CD patients as-
sessed by Beck Depression Score (BDS). Moreover, 
improvement was signifi cantly higher in painful CD.
Conclusions: Th e data confi rm that BTX-A thera-
py is able to induce signifi cant amelioration of several 
aspect of HRQL in CD patients.
